166 related articles for article (PubMed ID: 8599861)
1. Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy.
Bhagwatwar HP; Phadungpojna S; Chow DS; Andersson BS
Cancer Chemother Pharmacol; 1996; 37(5):401-8. PubMed ID: 8599861
[TBL] [Abstract][Full Text] [Related]
2. Development and characterization of an organic solvent free, proliposomal formulation of Busulfan using quality by design approach.
Chobisa D; Patel K; Monpara J; Patel M; Vavia P
Int J Pharm; 2018 Jan; 535(1-2):360-370. PubMed ID: 29126906
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and distribution of liposomal busulfan in the rat: a new formulation for intravenous administration.
Hassan M; Hassan Z; Nilsson C; Rehim MA; Kumlien S; Elfsson B; Kållberg N
Cancer Chemother Pharmacol; 1998; 42(6):471-8. PubMed ID: 9788573
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxicity of dimethylacetamide and pharmacokinetics in children receiving intravenous busulfan.
Hempel G; Oechtering D; Lanvers-Kaminsky C; Klingebiel T; Vormoor J; Gruhn B; Boos J
J Clin Oncol; 2007 May; 25(13):1772-8. PubMed ID: 17470868
[TBL] [Abstract][Full Text] [Related]
5. Oral formulation of a novel antiviral agent, PG301029, in a mixture of gelucire 44/14 and DMA (2:1, wt/wt).
He Y; Johnson JL; Yalkowsky SH
AAPS PharmSciTech; 2005 Apr; 6(1):E1-5. PubMed ID: 16353952
[TBL] [Abstract][Full Text] [Related]
6. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation.
Ansari M; Théoret Y; Rezgui MA; Peters C; Mezziani S; Desjean C; Vachon MF; Champagne MA; Duval M; Krajinovic M; Bittencourt H;
Ther Drug Monit; 2014 Feb; 36(1):93-9. PubMed ID: 24061446
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of effects of busulfan and DMA on SOS in pediatric stem cell recipients.
Kerl K; Diestelhorst C; Bartelink I; Boelens J; Trame MN; Boos J; Hempel G
Pediatr Blood Cancer; 2014 Feb; 61(2):306-11. PubMed ID: 24174393
[TBL] [Abstract][Full Text] [Related]
8. I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients.
Nguyen L; Fuller D; Lennon S; Leger F; Puozzo C
Bone Marrow Transplant; 2004 May; 33(10):979-87. PubMed ID: 15064687
[TBL] [Abstract][Full Text] [Related]
9. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies.
Tran HT; Madden T; Petropoulos D; Worth LL; Felix EA; Sprigg-Saenz HA; Choroszy M; Danielson M; Przepiorka D; Chan KW
Bone Marrow Transplant; 2000 Sep; 26(5):463-70. PubMed ID: 11019834
[TBL] [Abstract][Full Text] [Related]
10. Weight-based strategy of dose administration in children using intravenous busulfan: clinical and pharmacokinetic results.
Michel G; Valteau-Couanet D; Gentet JC; Esperou H; Socié G; Méchinaud F; Doz F; Neven B; Bertrand Y; Galambrun C; Demeocq F; Yakouben K; Bordigoni P; Frappaz D; Nguyen L; Vassal G
Pediatr Blood Cancer; 2012 Jan; 58(1):90-7. PubMed ID: 21254374
[TBL] [Abstract][Full Text] [Related]
11. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study.
Nguyen L; Leger F; Lennon S; Puozzo C
Cancer Chemother Pharmacol; 2006 Jan; 57(2):191-8. PubMed ID: 16133536
[TBL] [Abstract][Full Text] [Related]
12. Pre-formulation investigations for establishing a protocol for treosulfan handling and activation.
El-Serafi I; Loy O; Zhao Y; Oerther S; Mattsson J
Pharm Dev Technol; 2019 Jun; 24(5):639-648. PubMed ID: 30474459
[TBL] [Abstract][Full Text] [Related]
13. The pharmacokinetics and safety of twice daily i.v. BU during conditioning in pediatric allo-SCT recipients.
Le Gall JB; Milone MC; Waxman IM; Shaw LM; Harrison L; Duffy D; van de Ven C; Militano O; Geyer MB; Morris E; Bhatia M; Satwani P; George D; Garvin JH; Bradley MB; Schwartz J; Baxter-Lowe LA; Cairo MS
Bone Marrow Transplant; 2013 Jan; 48(1):19-25. PubMed ID: 22684047
[TBL] [Abstract][Full Text] [Related]
14. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa).
Bouligand J; Boland I; Valteau-Couanet D; Deroussent A; Kalifa C; Hartmann O; Vassal G
Bone Marrow Transplant; 2003 Nov; 32(10):979-86. PubMed ID: 14595385
[TBL] [Abstract][Full Text] [Related]
15. Busulfan dosing (Q6 or Q24) with adjusted or actual body weight, does it matter?
Clemmons AB; Evans S; DeRemer DL; Awan FT
J Oncol Pharm Pract; 2015 Dec; 21(6):425-32. PubMed ID: 24986792
[TBL] [Abstract][Full Text] [Related]
16. Busulphan in blood and marrow transplantation: dose, route, frequency and role of therapeutic drug monitoring.
Nath CE; Shaw PJ
Curr Clin Pharmacol; 2007 Jan; 2(1):75-91. PubMed ID: 18690856
[TBL] [Abstract][Full Text] [Related]
17. Lorazepam for seizure prophylaxis during high-dose busulfan administration.
Chan KW; Mullen CA; Worth LL; Choroszy M; Koontz S; Tran H; Slopis J
Bone Marrow Transplant; 2002 Jun; 29(12):963-5. PubMed ID: 12098063
[TBL] [Abstract][Full Text] [Related]
18. Monitoring of N,N-dimethylacetamide in children during i.v.-busulfan therapy by liquid chromatography-mass spectrometry.
Oechtering D; Boos J; Hempel G
J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Jul; 838(2):129-34. PubMed ID: 16725388
[TBL] [Abstract][Full Text] [Related]
19. Physiologically based pharmacokinetic modelling of Busulfan: a new approach to describe and predict the pharmacokinetics in adults.
Diestelhorst C; Boos J; McCune JS; Russell J; Kangarloo SB; Hempel G
Cancer Chemother Pharmacol; 2013 Nov; 72(5):991-1000. PubMed ID: 24061863
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of dimethylacetamide in children during standard and once-daily IV busulfan administration.
Trame MN; Bartelink IH; Boos J; Boelens JJ; Hempel G
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1149-55. PubMed ID: 24036908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
